Back to search results

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Abroad (travel likely)RecruitingPHASE2

Conditions

Breast Cancer · Triple Negative Breast Cancer · PD-L1 Negative

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Stamford Hospital, Stamford, Connecticut, United States

    Contact: Study coordinator (K.M. Steve Lo, MD) · slo@stamhealth.org
    Contact: Principal Investigator (K.M. Steve Lo, MD)

  • Miami Cancer Institute at Baptist Health (Kendall), Miami, Florida, United States

    Contact: Study coordinator (Lauren Carcas, MD) · laurencar@baptisthealth.net
    Contact: Principal Investigator (Lauren Carcas, MD)

  • Miami Cancer Institute at Baptist Health, Plantation, Florida, United States

    Contact: Study coordinator (Lauren Carcas, MD) · laurencar@baptisthealth.net
    Contact: Principal Investigator (Lauren Carcas, MD)

  • University of Chicago Medical Center, Chicago, Illinois, United States

    Contact: Study coordinator (Rita Nanda, MD) · rnanda@medicine.bsd.uchicago.edu
    Contact: Principal Investigator (Rita Nanda, MD)

  • Eastern Maine Medical Center, Brewer, Maine, United States

    Contact: Study coordinator (Sarah Sinclair, DO) · ssinclair@emhs.org
    Contact: Principal Investigator (Sarah Sinclair, DO)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Ana C. Garrido-Castro, MD) · Ana_Garrido-Castro@dfci.harvard.edu · 617-632-6409
    Contact: Principal Investigator (Ana C. Garrido-Castro, MD)

  • DFCI @ Foxborough, Foxborough, Massachusetts, United States

    Contact: Study coordinator (Natalie Sinclair, MD) · Nsinclair1@partners.org
    Contact: Principal Investigator (Natalie Sinclair, MD)

  • DFCI @ Milford Regional Hospital, Milford, Massachusetts, United States

    Contact: Study coordinator (Natalie Sinclair, MD) · nsinclair1@partners.org
    Contact: Principal Investigator (Natalie Sinclair, MD)

  • DF/BWCC in Clinical Affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States

    Contact: Study coordinator (Thomas P O'Connor, MD) · ThomasP_O'Connor@DFCI.HARVARD.EDU
    Contact: Principal Investigator (Thomas P O'Connor, MD)

  • The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

    Contact: Study coordinator (Emily Ray, MD) · emmi@ad.unc.edu
    Contact: Principal Investigator (Emily Ray, MD)

  • The Christ Hospital Cancer Center, Cincinnati, Ohio, United States

    Contact: Study coordinator (Julie Specht, MD) · julie.specht@thechristhospital.com
    Contact: Principal Investigator (Julie Specht, MD)

  • Ohio State University Medical Center, Columbus, Ohio, United States

    Contact: Study coordinator (Margaret Gatti-Mays, MD) · margaret.gatti-mays@osumc.edu
    Contact: Principal Investigator (Margaret Gatti-Mays, MD)

  • University of Pennsylvania-Abramson Cancer Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Payal Shah, MD) · payal.shah@pennmedicine.upenn.edu
    Contact: Principal Investigator (Payal Shah, MD)

  • Medical University of South Carolina, Charleston, South Carolina, United States

    Contact: Study coordinator (Abirami Sivapiragasam, MD)
    Study coordinator · sivapira@musc.edu
    Contact: Principal Investigator (Abirami Sivapiragasam, MD)

  • Sarah Cannon Research Institute, Chattanooga, Tennessee, United States

    Contact: Study coordinator (Brooke R Daniel, MD) · bdaniel@tnonc.com
    Contact: Principal Investigator (Brooke R Daniel, MD)
Study leads

  • Ana C Garrido-Castro, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)